Form 144 CODEXIS For: 21 November
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Codexis Inc (CDXS)
Codexis Inc stock price live, this page displays NASDAQ CDXS stock exchange data. View the CDXS premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Codexis Inc real time stock price chart below.
What Is the Codexis Inc Stock Price Today?
The Codexis Inc stock price today is 1.730.
What Is the Stock Symbol for Codexis Inc?
The stock symbol for Codexis Inc is ""CDXS.""
What Stock Exchange Does Codexis Inc Trade On?
Codexis Inc is listed and trades on the NASDAQ stock exchange.
Is Codexis Inc a Good Stock to Buy?
Determining whether Codexis Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CDXS quote. (ISIN: US1920051067)
What Is the Codexis Inc Stock Price Today?
The Codexis Inc stock price today is 1.730.
What Is the Stock Symbol for Codexis Inc?
The stock symbol for Codexis Inc is ""CDXS.""
What Stock Exchange Does Codexis Inc Trade On?
Codexis Inc is listed and trades on the NASDAQ stock exchange.
Is Codexis Inc a Good Stock to Buy?
Determining whether Codexis Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the CDXS quote. (ISIN: US1920051067)
Fair Value
An estimate of a Codexis's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.720
1.790
52 wk Range
1.520
6.080
CDXS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Codexis's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.7201.790
52 wk Range
1.5206.080
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CDXS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Codexis's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
6.583
Upside
+280.54%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Form 13G Codexis For: 14 November
- Investing.com
- Form 13G Codexis For: 14 November
- Investing.com
- Form 144 CODEXIS For: 21 November
- Investing.com
- Form 13G Codexis For: 14 November
- Investing.com
- Form 13G Codexis For: 14 November
- Investing.com
- Form 13G CODEXIS For: 7 November
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Codexis Inc Company Profile
Codexis, Inc. provides enzymatic solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, and enhance novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China. The company develops its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. It has a license agreement with Aldevron LLC and Pfizer Inc. The company was incorporated in 2002 and is headquartered in Redwood City, California.
Codexis Inc SWOT Analysis
Enzymatic Revolution | Codexis pivots to RNAi therapeutics manufacturing, leveraging its ECO Synthesis platform to address critical challenges in drug production scalability and efficiency |
Market Opportunity | Explore the billion-dollar potential in the growing RNAi therapeutics market, where Codexis aims to revolutionize manufacturing processes with its innovative approach |
Financial Fortitude | Delve into Codexis's robust financial position, with $90.3 million in cash reserves providing runway until 2027, despite current negative EBITDA of -$45.78 million |
Analyst Outlook | Cantor Fitzgerald maintains a consistent $11.00 price target throughout 2024, reflecting cautious optimism about Codexis's potential in the RNAi manufacturing arena |
Codexis Inc Earnings Call Summary for Q3/2025
- Codexis reported Q3 2025 revenue of $8.6 million, missing forecasts of $18.66 million with EPS loss of $0.22, triggering a 5.35% stock price drop to $2.15.
- Revenue declined 32.8% year-over-year while gross margin improved to 64% from 61%; the company maintains a cash position of $58.7 million excluding Merck agreement funds.
- Strategic pivot from enzyme development to oligonucleotide manufacturing and siRNA therapeutics market is underway, with CEO Stephen Dilly emphasizing evolution to 'manufacturing solutions provider.'
- Despite Q3 shortfall, management projects meeting or exceeding the top-end of 2025 revenue guidance and plans to extend operational runway through 2027.
- Company faces challenges including pricing pressure in enzyme development, potential operational hurdles in siRNA manufacturing transition, and uncertain market acceptance of new solutions.
Last Updated: 06/11/2025, 23:34
Read Full TranscriptCompare CDXS to Peers and Sector
Metrics to compare | CDXS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCDXSPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.4x | −5.4x | −0.6x | |
PEG Ratio | −0.17 | −0.08 | 0.00 | |
Price/Book | 4.1x | 1.5x | 2.6x | |
Price / LTM Sales | 3.0x | 4.3x | 3.3x | |
Upside (Analyst Target) | 304.6% | 85.1% | 38.3% | |
Fair Value Upside | Unlock | 7.0% | 4.5% | Unlock |
Analyst Ratings
5 Buy
2 Hold
0 Sell
Ratings:
7 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 6.583
(+280.54% Upside)
Earnings
Latest Release
Nov 06, 2025
EPS / Forecast
-0.22 / -0.15
Revenue / Forecast
8.60M / 18.66M
People Also Watch
FAQ
What Stock Exchange Does Codexis Trade On?
Codexis is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Codexis?
The stock symbol for Codexis is "CDXS."
What Is the Codexis Market Cap?
As of today, Codexis market cap is 156.26M.
What Is Codexis's Earnings Per Share (TTM)?
The Codexis EPS (TTM) is -0.75.
When Is the Next Codexis Earnings Date?
Codexis will release its next earnings report on 25 Feb 2026.
From a Technical Analysis Perspective, Is CDXS a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Codexis Stock Split?
Codexis has split 0 times.
How Many Employees Does Codexis Have?
Codexis has 188 employees.
What is the current trading status of Codexis (CDXS)?
As of 01 Dec 2025, Codexis (CDXS) is trading at a price of 1.730, with a previous close of 1.730. The stock has fluctuated within a day range of 1.720 to 1.790, while its 52-week range spans from 1.520 to 6.080.
What Is Codexis (CDXS) Price Target According to Analysts?
The average 12-month price target for Codexis is USD6.58333, with a high estimate of USD11 and a low estimate of USD2. 5 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +280.54% Upside potential.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.